Pivotal trials provide hope in addressing anti-VEGF therapy burdens: Treatment and monitoring advancements could reduce number of injections.

8 retina retina APRIL 2021:: Ophthalmology Times Europe® Pivotal trials provide hope in addressing anti-VEGF therapy burdens Treatment and monitoring advancements could reduce number of injections By Cheryl Guttman Krader; Reviewed by Dr Anat Loewenstein D ual inhibition of vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2) using intravitreal bispecific antibody faricimab (Roche) is an effective strategy with promising durability for treating both neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME), according to results from four pivotal trials reported at the Angiogenesis, Exudation, and Degeneration 2021 Virtual Symposium. The OCT data showed that in the faricimab arm, 45% of patients were able to maintain disease control with a treatment interval >=12 weeks and 45% of patients needed retreatment just every 16 weeks.